Jingze Biopharmaceutical (Hefei) Co., Ltd. Makes Third HKEX Listing Filing, CICC and Guoyuan International Act as Joint Sponsors
NewTimeSpace News: Jingze Biopharmaceutical (Hefei) Co., Ltd. filed its third listing application with HKEX on 3 July 2026, jointly sponsored by CICC and Guoyuan International.
Founded in 2014, the Company is a biopharmaceutical enterprise concentrating on assisted reproductive medicine and ophthalmic medicine. Its two core products are as follows: JZB30 is a recombinant human follicle-stimulating hormone injection for registration, indicated for ovulation induction in assisted reproductive therapy and infertility caused by hypogonadotropic hypogonadism; JZB05 is an anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection candidate developed to treat fundus neovascular diseases including wet age-related macular degeneration and diabetic macular oedema. In addition, the Company boasts six other pipeline drug candidates.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- Biotech Index Hits a Year-to-Date High as Innovative Drug and CXO Names Rally; CSOP Hang Seng Biotech ETF (3174.HK) Gains 3.18% and Is Up 17.93% Year-to-Date
- Korean Stocks Open Higher but Close Lower as Semiconductor Heavyweights Slip; Csop Kospi 200 Etf (03121.HK) Falls 1.30%
- AOM INT'L (00381.HK): Launches Twelve Dynasties Wine Project Combining Cultural Export and Digital Assets
- KINETIC DEV (01277.HK): Sierra Leone Rutile Project Commences Production
- CNE TECH CORP (00611.HK): Acquisition Consideration Adjusted Down to RMB71.93m
